Royal DSM, the global Life Sciences and Materials Sciences company, announces the following:
Marcel Wubbolts, currently Vice President R&D DSM Innovation Center, will assume the position of Chief Technology Officer for DSM as of October 1, reporting to Rob van Leen, Chief Innovation Officer.
Marcel holds a PhD from the University of Groningen, NL, was post-doc and Assistent Professor at the ETH in Zürich. He joined DSM as a senior scientist and became Managing Director of DSM Biotech GmbH, in Jülich, Germany. Thereafter, he was Competence Manager Biocatalysis & Biotransformations and then became Program Director at the DSM Innovation Center in Delft, the Netherlands, running the Industrial (White) Biotechnology program. Since January 2011 he is at his current position.
Marcel has published over 80 publications and patents in the area of biocatalysis and metabolic engineering. He serves on the board of the WG Applied Biocatalysis of the Dutch Society for Biotechnology (NBV); the board of the European Federation of Biotechnology Section on Applied Biocatalysis (ESAB); the Industrial Biotechnology council of EuropaBio; the supervisory board of ERA-NET Industrial Biotechnology and leads the Industrial Biotechnology Section of Suschem, European Technology Platform for Sustainable Chemistry.
Marcel will succeed Jos Put who will continue to be an advisor to DSM e.g. in the field of material sciences and for several of the DSM Science and Technology awards.
DSM - Bright Science. Brighter Living.™
Royal DSM N.V. is a global science-based company active in health, nutrition and materials. By connecting its unique competences in Life Sciences and Materials Sciences DSM is driving economic prosperity, environmental progress and social advances to create sustainable value for all stakeholders. DSM delivers innovative solutions that nourish, protect and improve performance in global markets such as food and dietary supplements, personal care, feed, pharmaceuticals, medical devices, automotive, paints, electrical and electronics, life protection, alternative energy and bio-based materials. DSM's 22,000 employees deliver annual net sales of about EUR 9 billion. The company is listed on NYSE Euronext. More information can be found at www.dsm.com